Core Insights - China Mengniu Dairy Company Limited is actively advancing the A-round financing for its synthetic biology subsidiary, Hongmo Biotechnology, with a significantly increased valuation compared to the previous round [1][2] - The strategic focus on Human Milk Oligosaccharides (HMO) and innovative product development positions Mengniu favorably in the dairy industry [2] Group 1: Financing and Valuation - Hongmo Biotechnology is undergoing A-round financing, attracting multiple investment institutions for due diligence, indicating strong market interest [1] - The company completed a Pre-A round financing of over 100 million yuan in June 2024, led by CICC Qide Fund, with funds allocated for new product development and commercialization [1][2] Group 2: Strategic Development and Innovation - Mengniu's strategic layout for HMO dates back to 2016, establishing a comprehensive innovation system from basic research to industrialization [2] - Hongmo Biotechnology won the "Best Startup Brand Award" at the 2025 World Dairy Innovation Awards, marking a significant achievement for Chinese functional nutrition technology [2] - Mengniu has successfully integrated HMO technology into various products, including the Ruibaoen series of milk powder and the Future Star HMO children's liquid formula, demonstrating a proactive response to nutritional demands in the new health era [2]